Madrigal Pharmaceuticals (MDGL) Profit After Tax (2019 - 2025)
Historic Profit After Tax for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to -$114.2 million.
- Madrigal Pharmaceuticals' Profit After Tax fell 675.55% to -$114.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$289.1 million, marking a year-over-year increase of 4425.49%. This contributed to the annual value of -$465.9 million for FY2024, which is 2469.56% down from last year.
- According to the latest figures from Q3 2025, Madrigal Pharmaceuticals' Profit After Tax is -$114.2 million, which was down 675.55% from -$42.3 million recorded in Q2 2025.
- In the past 5 years, Madrigal Pharmaceuticals' Profit After Tax ranged from a high of -$42.3 million in Q2 2025 and a low of -$152.0 million during Q2 2024
- Its 5-year average for Profit After Tax is -$84.5 million, with a median of -$76.9 million in 2023.
- As far as peak fluctuations go, Madrigal Pharmaceuticals' Profit After Tax crashed by 9187.08% in 2024, and later soared by 7217.82% in 2025.
- Over the past 5 years, Madrigal Pharmaceuticals' Profit After Tax (Quarter) stood at -$64.5 million in 2021, then tumbled by 33.08% to -$85.9 million in 2022, then crashed by 30.6% to -$112.2 million in 2023, then skyrocketed by 47.03% to -$59.4 million in 2024, then tumbled by 92.16% to -$114.2 million in 2025.
- Its Profit After Tax stands at -$114.2 million for Q3 2025, versus -$42.3 million for Q2 2025 and -$73.2 million for Q1 2025.